"我们能治愈IgG4相关的疾病吗?"
Kazuichi Okazaki1, Tsukasa Ikeura2, Kazushige Uchida3
1Department of Internal Medicine, Kansai Medical University Kori Hospital, Neyagawa, Osaka 572-8551, Japan.
Current opinion in immunology
|May 21, 2025
概括
免疫球蛋白G4相关疾病 (IgG4-RD) 是一种罕见的,慢性,多器官疾病. 未来的治疗可能会向与IgG4-RD病原发生有关的等离子体细胞,B细胞和特定的T细胞.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 病理学 病理学 病理学
背景情况:
- 与IgG4相关的疾病 (IgG4-RD) 是一种新的,罕见的,慢性,免疫介导的纤维炎症疾病.
- 它影响多个器官,其致病机制尚未完全理解.
- 潜在的因素包括遗传学,抗原和异常免疫反应.
研究的目的:
- 审查目前对IgG4相关疾病 (IgG4-RD) 病原学的理解.
- 讨论目前IgG4-RD的治疗策略.
- 确定IgG4-RD.的有希望的未来治疗点.
主要方法:
- 对IgG4相关疾病 (IgG4-RD) 的文献综述.
- 对参与IgG4-RD病原发生的免疫细胞的分析.
- 对IgG4-RD.目前和潜在的未来疗法的评估.
主要成果:
- 多种免疫细胞,包括中性粒细胞外细胞陷,M2巨细胞,血清细胞,B细胞和各种T细胞 (Th2-CD4+T,Tfh,CD4+SLAMF7+细胞毒性T细胞),都与IgG4-RD有关.
- 传统疗法包括葡萄糖皮质类药物或rituximab,通常与免疫调节剂一起.
- 有限的随机临床试验阻碍了全面管理的建立.
结论:
- 目前对IgG4-RD的治疗依赖于传统疗法,但由于临床试验很少,缺乏全面的策略.
- 向血质细胞,B细胞和CD4+SLAMF7+细胞毒性T细胞显示出未来IgG4-RD治疗的前景.
- 需要进一步的研究和临床试验,以建立IgG4-RD.的最终管理协议.
更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
84
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
84
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
126
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
126
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Hypersensitivities
474
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
474
Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115


